Drug
Envudeucitinib clinical trials
Also written ESK-001.
- studies test it
- 11
- open now
- 0
- in phase 3
- 2
- first study started
- 2022
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
11 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 4
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Alumis Inc (11)
Studies
Open first, then newest update. How each study uses envudeucitinib is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3Alumis IncNCT06586112Written as Envudeucitinib
- A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001CompletedPhase 3Alumis IncNCT06588738Written as Envudeucitinib
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisActive, not recruitingPhase 2Alumis IncNCT05739435Written as envudeucitinib
- Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusActive, not recruitingPhase 2Alumis IncNCT05966480Written as Envudeucitinib
- An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver DamageCompletedPhase 1Alumis IncNCT06952634Written as envudeucitinib
- An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001CompletedPhase 1Alumis IncNCT07378579Written as ESK-001
- An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal FunctionCompletedPhase 1Alumis IncNCT06962774Written as ESK-001
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisCompletedPhase 2Alumis IncNCT05600036Written as ESK-001
- POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUTerminatedPhase 2Alumis IncNCT05953688Written as ESK-001
- Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy ParticipantsCompletedPhase 1Alumis IncNCT05330858Written as ESK-001
- Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy ParticipantsCompletedPhase 1Alumis IncNCT05431634Written as Experimental drug: ESK-001
Codes
What other systems call envudeucitinib · ClinicalTrials.gg INT017053
- UNII (FDA) KD2MDJ4GABENVUDEUCITINIBOne source FDA
- NCI Thesaurus C206909EnvudeucitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KD2MDJ4GAB | ENVUDEUCITINIB | One source FDA |
| NCI Thesaurus | C206909 | Envudeucitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.